256 filings
Page 3 of 13
8-K
7sp5y31l0det q3p77g
14 Nov 22
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
uzk wa6eiw
2 Nov 22
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
4:05pm
8-K
hsbb5eq4w5
21 Oct 22
Matinas BioPharma Announces Positive Interim Data from the Phase 2
7:00am
8-K
5qsuvpt
13 Sep 22
Regulation FD Disclosure
7:00am
8-K
xhdmpo
11 Aug 22
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
6:25am
8-K
e4rsvteb
12 May 22
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
6:30am
8-K
cintu4q4 fd
13 Apr 22
Regulation FD Disclosure
8:43am
8-K
pdswtohaxz82mmrbu45
11 Apr 22
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
7:00am
S-8
v6p01i0zd5 4walrgdp
1 Apr 22
Registration of securities for employees
5:25pm
8-K
h7ozlxav
8 Mar 22
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
6:30am
8-K
q07gw
25 Jan 22
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
6:30am
8-K
2zzqpd w1hd944bq
16 Dec 21
Regulation FD Disclosure
6:30am
8-K
rggn3
6 Dec 21
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
6:30am